Zahlen für Q1/21

• keine Umsätze
  
• Verlust 13 Mio. $
  
• Cash 142 Mio. $
  
• MK 247 Mio. $
  

KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022

"The last patient from the MISSION Phase 1b completed treatment in February 2021, and final clinical data from this 25-week safety and tolerability study of up to 75 mg weekly of KZR-616 in 47 patients with SLE will be presented during the European Congress of Rheumatology (EULAR 2021) in June."

"The amended Phase 2 open-label portion of the MISSION trial in patients with active, proliferative lupus nephritis opened for enrollment in August 2020 and is actively recruiting."

Interim data are expected in late 2021, and topline data are expected in the first half of 2022.

https://www.kezarlifesciences.com/investors/...rter-financial-results

Zahlen für Q2/21

• keine Umsätze
  
• Verlust 13 Mio. $
  
• Cash 129 Mio. $
  
• MK 281 Mio. $
  

-  KZR-616 MISSION Phase 1b study results support continued development for multiple immune mediated diseases

-  Investigational new drug (IND) application filed for first-in-class protein secretion inhibitor, KZR-261

- Phase 2 open-label portion of the MISSION trial expects interim data to be reported in Q4 2021, and topline data are expected in the first half of 2022

https://www.kezarlifesciences.com/investors/...cond-quarter-financial

erster Patient in Phase 1 Studie (KZR-261) dosiert

https://www.kezarlifesciences.com/investors/...ed-in-phase-1-trial-of

positive Zwischenergebnisse der Phase 2 MISSION Studie KZR-616 (in LN)

https://www.kezarlifesciences.com/investors/...terim-results-from-the

Topline-Ergebnisse aus der PRESIDIO-Studie mit Zetomipzomib (KZR-616)

• zur Behandlung von Dermatomyositis (DM) und Polymyositis (PM)
  
• der primäre Endpunkt sah keine Unterschiede zum Placebo
  

https://www.kezarlifesciences.com/investors/...from-presidio-trial-of

Zahlen für Q1/22

• keine Umsätze
  
• Verlust 16 Mio. $
  
• Cash 243 Mio. $
  
• MK 301 Mio. $
  

https://www.kezarlifesciences.com/investors/...quarter-2022-financial

Spekulative Wette auf die kommenden Studiendaten (LN).

positive Phase 2 MISSION-Studienergebnisse (LN)

https://ir.kezarlifesciences.com/news-releases/...ine-results-mission

Schöner Verdoppler in einem Monat.

Zahlen für Q4/22

• keine Umsätze
  
• Verlust 18 Mio. $
  
• Cash 277 Mio. $
  
• MK 229 Mio. $
  

https://ir.kezarlifesciences.com/news-releases/...r-and-year-end-2022